Trial · NCT02303821
Results by group136
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 136
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 1 (20 mg/m^2) | Dose Escalation 1 - Lead in Cycle Day 1 | 927 | Standard Deviation 259 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | Dose Escalation 1 - Lead in Cycle Day 1 | 637 | Standard Deviation 241 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 1 (20 mg/m^2) | Induction cycle Day 8 | 771 | Standard Deviation 151 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | Induction cycle Day 8 | 792 | Standard Deviation 580 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 2 (20/27 mg/m^2) | Induction cycle Day 8 | 445 | Standard Deviation 260 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 2 (20/36 mg/m^2) | Induction cycle Day 8 | 1070 | Standard Deviation 359 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 2 (20/45 mg/m^2) | Induction cycle Day 8 | 1630 | Standard Deviation 875 | ng/mL |
| Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination | Phase 1b: Dose Escalation 2 (20/56 mg/m^2) | Induction cycle Day 8 | 11200 | Standard Deviation 16400 | ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 1 (20 mg/m^2) | Dose Escalation 1 - Lead in Cycle Day 1 | 387 | Standard Deviation 125 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | Dose Escalation 1 - Lead in Cycle Day 1 | 240 | Standard Deviation 113 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 1 (20 mg/m^2) | Induction Cycle Day 8 | 361 | Standard Deviation 160 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | Induction Cycle Day 8 | 374 | Standard Deviation 273 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 2 (20/27 mg/m^2) | Induction Cycle Day 8 | 214 | Standard Deviation 155 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 2 (20/36 mg/m^2) | Induction Cycle Day 8 | 529 | Standard Deviation 210 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 2 (20/45 mg/m^2) | Induction Cycle Day 8 | 829 | Standard Deviation 479 | hr*ng/mL |
| Phase 1b: Area Under the Curve (AUC) From Time 0 to the Last Quantifiable Timepoint (AUClast) of Carfilzomib | Phase 1b: Dose Escalation 2 (20/56 mg/m^2) | Induction Cycle Day 8 | 4000 | Standard Deviation 6370 | hr*ng/mL |
| Phase 1b: AUC From Time 0 to Infinity (AUCinf) of Carfilzomib | Phase 1b: Dose Escalation 1 (20 mg/m^2) | Dose Escalation 1 - Lead in Cycle Day 1 | 387 | Standard Deviation 124 | hr*ng/ mL |
| Phase 1b: AUC From Time 0 to Infinity (AUCinf) of Carfilzomib | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | Dose Escalation 1 - Lead in Cycle Day 1 | 268 | Standard Deviation 101 | hr*ng/ mL |
| Phase 1b: AUC From Time 0 to Infinity (AUCinf) of Carfilzomib | Phase 1b: Dose Escalation 1 (20 mg/m^2) | Induction Cycle Day 8 | 368 | Standard Deviation 184 | hr*ng/ mL |
| Phase 1b: AUC From Time 0 to Infinity (AUCinf) of Carfilzomib | Phase 1b: Dose Escalation 1 (20/27 mg/m^2) | Induction Cycle Day 8 | 374 | Standard Deviation 273 | hr*ng/ mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02303821/results